Investor Presentaiton

Sotyktu (TYK-2 inhibitor) Oncology Hematology Cell Therapy Immunology Cardiovascular Alopecia Areata (AA) Phase II IM011-134 - N = 90 Indication Phase/Study # of Patients Design • • Sotyktu Dose 1 Sotyktu Dose 2 Placebo, followed by Sotyktu Dose 1 or Dose 2 Primary: Change from baseline in SALT score at Week 24 Endpoints • Expected data readout 2024 Status CT Identifier ll Bristol Myers Squibb Q3 2023 Results NCT05556265 Not for Product Promotional Use 51

View entire presentation